Home » Stocks » BOLT

Bolt Biotherapeutics, Inc. (BOLT)

Stock Price: $30.03 USD 1.25 (4.34%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 1.04B
Revenue (ttm) 296,000
Net Income (ttm) -39.06M
Shares Out 34.52M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $30.03
Previous Close $28.78
Change ($) 1.25
Change (%) 4.34%
Day's Open 28.60
Day's Range 26.55 - 30.40
Day's Volume 157,778
52-Week Range 22.63 - 35.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public o...

GlobeNewswire - 1 month ago

REDWOOD CITY, Calif.-- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced...

NASDAQ - 1 month ago

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 1 month ago

Bolt Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

About BOLT

We are a clinical-stage immuno-oncology company developing tumor-targeted therapies. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems by activating and recruiting myeloid cells, thereby re-programming the tumor microenvironment to invoke an adaptive immune response. We believe that this process leads to the development of systemic immunological memory achi... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Feb 5, 2021
CEO
Randall C. Schatzman, Ph.D.
Employees
63
Stock Exchange
NASDAQ
Ticker Symbol
BOLT
Full Company Profile

Financial Performance

Financial Statements